Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
133M
-
Shares change
-
+15.6M
-
Total reported value, excl. options
-
$663M
-
Value change
-
+$77.6M
-
Put/Call ratio
-
1.82
-
Number of buys
-
80
-
Number of sells
-
-77
-
Price
-
$4.97
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2023
203 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q2 2023.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 133M shares
of 226M outstanding shares and own 58.97% of the company stock.
Largest 10 shareholders include FMR LLC (24.9M shares), TPG GP A, LLC (18.7M shares), STATE STREET CORP (8.48M shares), BlackRock Inc. (8.45M shares), VANGUARD GROUP INC (7.5M shares), JPMORGAN CHASE & CO (6.13M shares), PRIMECAP MANAGEMENT CO/CA/ (5.64M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.33M shares), Woodline Partners LP (5.31M shares), and CITADEL ADVISORS LLC (4.74M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.